文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]FAP-2286的临床前研究与首次人体显像及与2-[18F]FDG PET/CT在多种癌症患者中的比较

Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-08

本研究在临床前评估新型成纤维细胞活化蛋白(FAP)特异性示踪剂[18F]FAP-2286,并在15例多种癌症患者中开展首次人体显像,与2-[18F]FDG PET进行比较。结果显示[18F]FAP-2286放化产率为30.53±5.20%、放化纯度超过97%,在荷瘤小鼠和癌症患者中均见快速、高靶点摄取和满意滞留,可能成为低糖代谢恶性肿瘤PET显像的替代选择。

要点

  • [18F]FAP-2286放化产率30.53±5.20%,放化纯度超过97%。
  • 在荷瘤小鼠和癌症患者中观察到快速、高靶点摄取及满意肿瘤滞留。
  • 临床研究显示其可能成为胃癌等低糖代谢恶性肿瘤PET显像的替代选择。

核心结论

  • [18F]FAP-2286在荷瘤小鼠和癌症患者中均表现出快速、高靶点摄取和满意滞留的优良显像质量。
  • 它可能成为早期或延迟期显像以及2-[18F]FDG不摄取癌症PET扫描的有前景候选示踪剂。

研究设计与样本

  • 临床前研究:按照药品生产质量管理规范(GMP)手动合成[18F]FAP-2286,用HT-1080hFAP细胞系进行细胞摄取、竞争性结合亲和力、内化和外排实验。
  • 在HEK-293ThFAP、A549hFAP、HT-1080hFAP荷瘤小鼠及HEK-293T、A549、HT-1080对照组中进行PET显像和生物分布研究。
  • 临床研究:在15例多种癌症患者中开展[18F]FAP-2286的首次人体临床评估,并与2-[18F]FDG PET进行比较。

主要发现

  • [18F]FAP-2286放化产率为30.53±5.20%,放化纯度超过97%。
  • 细胞实验中[18F]FAP-2286显示特异性摄取、高内化分数和低细胞外排。
  • micro-PET显像和癌症患者中均观察到快速肿瘤摄取和满意肿瘤滞留。
  • 临床研究显示[18F]FAP-2286可能成为胃癌等低糖代谢恶性肿瘤PET显像的替代选择。

临床怎么用

  • 作者认为[18F]FAP-2286可能成为早期或延迟期显像及2-[18F]FDG不摄取癌症PET扫描的有前景候选示踪剂。
  • 临床研究显示[18F]FAP-2286可能成为胃癌等低糖代谢恶性肿瘤PET显像的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fibroblast-activated protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) of many solid cancers, but low or absent in normal tissues. Our study aimed to develop a novel FAP-specific tracer, namely [18F]FAP-2286, and evaluated its performance in comparison with well-established agents such as [18F]FAPI-42 and [68Ga]Ga-FAP-2286 in preclinical research, as well as 2-[18F]FDG in pilot clinical study. METHODS: [18F]FAP-2286 was manually synthesized in accordance with Good Manufacturing Practice (GMP). Subsequent investigations encompassed cell uptake, competitive binding affinity, internalization and efflux assays using HT-1080hFAP cell lines. PET imaging and biodistribution studies were conducted in HEK-293ThFAP, A549hFAP, HT-1080hFAP tumor-bearing mice as well as HEK-293T, A549 and HT-1080 control groups. Furthermore, clinical evaluation of [18F]FAP-2286 was performed in fifteen patients with various cancers compared to 2-[18F]FDG PET. RESULTS: The radiolabeling yield of [18F]FAP-2286 was 30.53 ± 5.20%, with a radiochemical purity exceeding 97%. In cell assays, [18F]FAP-2286 showed specific uptake, high internalization fraction and low cellular efflux. Rapid tumor uptake and satisfactory tumor retention was observed on micro-PET imaging and cancer patients. Meanwhile, the clinical research demonstrated that [18F]FAP-2286 may represent an alternative for low glucose-metabolism malignant tumors PET imaging such as gastric cancers. CONCLUSION: [18F]FAP-2286 showed superior imaging quality including rapid and high target uptake and satisfactory retention in both tumor-bearing mice and cancer patients. It may emerge as a promising candidate for early or delayed phase imaging and 2-[18F]FDG non-avid cancers PET scan.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu L, Zhong J, Zhang Z, et al. Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients. Eur J Nucl Med Mol Imaging. 2024. PMID: 38326656. doi:10.1007/s00259-024-06626-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。